Nkarta, Inc. (NKTX)

NASDAQ: NKTX · Real-Time Price · USD
2.120
0.00 (0.00%)
At close: Sep 2, 2025, 4:00 PM
2.100
-0.020 (-0.94%)
After-hours: Sep 2, 2025, 4:20 PM EDT
Market Cap149.15M
Revenue (ttm)n/a
Net Income (ttm)-109.24M
Shares Out 71.02M
EPS (ttm)-1.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume375,091
Open2.130
Previous Close2.120
Day's Range2.085 - 2.180
52-Week Range1.310 - 6.628
Beta0.73
AnalystsStrong Buy
Price Target13.50 (+536.79%)
Earnings DateAug 12, 2025

About NKTX

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravi... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 157
Stock Exchange NASDAQ
Ticker Symbol NKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price target is $13.5, which is an increase of 536.79% from the latest price.

Price Target
$13.5
(536.79% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Nkarta to Participate in a September Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today ...

15 hours ago - GlobeNewsWire

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r...

21 days ago - GlobeNewsWire

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today a...

5 weeks ago - GlobeNewsWire

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Nkarta shares have remained flat since my last review in March, reflecting a wait-and-see market stance. Pipeline updates show steady progress, but no major catalysts have emerged; data readouts are e...

6 weeks ago - Seeking Alpha

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

3 months ago - GlobeNewsWire

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

Nkarta Inc.  NKTX on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 cents.

3 months ago - Benzinga

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded ...

3 months ago - GlobeNewsWire

Nkarta to Participate in an April Investor Conference

SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its p...

5 months ago - GlobeNewsWire

Nkarta: Grinding Lower, Trying To Find Support

Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with suff...

5 months ago - Seeking Alpha

Nkarta: Betting On The Turnaround

Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D...

5 months ago - Seeking Alpha

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Nkarta, Inc.  NKTX reported a fourth-quarter earnings report on Wednesday with a loss of 35 cents per share, beating the consensus of a loss of 41 cents.

5 months ago - Benzinga

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoim...

5 months ago - GlobeNewsWire

Nkarta to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa...

6 months ago - GlobeNewsWire

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts

9 months ago - GlobeNewsWire

Nkarta to Participate in an Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa...

10 months ago - GlobeNewsWire

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r...

10 months ago - GlobeNewsWire

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: AMNMRNA
11 months ago - Benzinga

Nkarta to Participate in Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its p...

1 year ago - GlobeNewsWire

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Nkarta, Inc. data from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory large B-cell lymphoma, expected by end of 2024. The global non-Hodgkin's Lymphoma Therapeu...

1 year ago - Seeking Alpha

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three d...

1 year ago - GlobeNewsWire

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r...

1 year ago - GlobeNewsWire

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that r...

1 year ago - GlobeNewsWire

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced change...

1 year ago - GlobeNewsWire

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis

1 year ago - GlobeNewsWire

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translat...

1 year ago - GlobeNewsWire